Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13248644 | 0.79 | MDM2 (0.51) | CFTRALDH1A1MAPK1TSHRHSD17B10 | |
| SCHEMBL14159142 | 0.77 | SMN1; SMN2 (0.55) | CFTRALDH1A1MEN1KMT2APOLB | |
| SCHEMBL3115397 | 0.73 | ALDH1A1 (0.50) | ALDH1A1MAPK1MEN1KMT2AHPGD | |
| SCHEMBL6652679 | 0.73 | CFTR (0.52) | CFTRALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5756856 | 0.73 | CFTR (0.54) | CFTRALDH1A1MEN1KMT2APOLB | |
| SCHEMBL6631450 | 0.71 | KMT2A (0.49) | CFTRALDH1A1MEN1KMT2APOLB | |
| SCHEMBL19032847 | 0.71 | CFTR (1.00) | CFTRALDH1A1LMNA | |
| SCHEMBL6468214 | 0.71 | AR (0.78) | ALDH1A1KDM4EARLMNASMN1; SMN2 | |
| SCHEMBL12343938 | 0.70 | CFTR (0.47) | CFTRALDH1A1KDM4EP2RX3SMN1; SMN2 | |
| SCHEMBL30928902 | 0.70 | CFTR (0.63) | CFTRALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| EP-1896428-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | Novartis AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136442-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | NOVARTIS AG (CH) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | CFTR 1638/4885ALDH1A1 1213/4885MAPK1 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.